1. Home
  2. CHGA vs ONCO Comparison

CHGA vs ONCO Comparison

Compare CHGA & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Change Agents Corporation Common Stock

CHGA

Change Agents Corporation Common Stock

N/A

Current Price

$0.79

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Logo Onconetix Inc.

ONCO

Onconetix Inc.

N/A

Current Price

$6.79

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CHGA
ONCO
Founded
2015
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0M
3.0M
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
CHGA
ONCO
Price
$0.79
$6.79
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
52.7K
★ 5.1M
Earning Date
11-17-2026
11-20-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 33.18
22.80
EPS
★ N/A
N/A
Revenue
N/A
★ $815,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.25
$0.09
52 Week High
$3.02
$644.00

Technical Indicators

Market Signals
Indicator
CHGA
ONCO
Relative Strength Index (RSI) 30.23 95.36
Support Level $0.25 $0.56
Resistance Level $2.54 $17.20
Average True Range (ATR) 0.16 0.23
MACD -0.08 0.44
Stochastic Oscillator 9.09 90.91

Price Performance

Historical Comparison
CHGA
ONCO

About CHGA Change Agents Corporation Common Stock

Change Agents Corp is an artificial intelligence software company focused on developing agentic AI applications designed to help small businesses, brands, and content creators increase revenue, improve digital discoverability, and automate content creation. The company's current portfolio includes Beacon, an AI Search Optimization platform, and Catch-Up, an autonomous AI-powered content creation platform. Through its scalable Software-as-a-Service (SaaS) business model, it is focused on delivering AI solutions that create measurable customer value while generating recurring subscription revenue and long-term shareholder returns.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Share on Social Networks: